Kaoru Funaki

To evaluate the efficacy of MRgFUS treatment of adenomyosis over a 2-year follow-up, symptom severity, alternative treatment and adverse events were examined. Thirty-nine women (mean age 40.9 years), with symptomatic adenomyosis who had com…

The efficacy of MRgFUS in the treatment of uterine adenomyosis and the attendant adverse events were evaluated at 12 months postoperatively. Thirty-nine women (mean age 40.9 ± 5.0 years) with symptomatic adenomyosis who had completed their …

We investigated the feasibility of ablating uterine adenomyosis by MR-guided focused ultrasound surgery (MRgFUS) and any adverse events that may arise during, immediately after and 1-week after MRgFUS. The subjects were 40 women with sympto…